A Randomized Trial Comparing two therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 Diabetes who were previously treated by basal insulin Glargine with either Metformin or Metformin and Sulfonylurea - GWDM

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 760

Inclusion Criteria

[1]Have T2DM (as defined by World Health Organization [WHO] classification)
[2]Are at least 18 years of age
[3]Have been taking a basal insulin Glargine, at dose of =20 units/day, for at least 3 months prior to visit 1
[4]Have been taking basal insulin Glargine at dose of =20 units/day, in combination with 1 of the following OAM regimens, for at least 3 months prior to visit 1
[a]Metformin or immediate-release metformin or extended-release metformin alone at a maximum tolerated and stable dose with no less than 500 mg/day for at least 6 weeks prior to visit 1.
Or
[b]Metformin or immediate-release metformin or extended-release metformin at a maximum tolerated and stable dose with no less than 500 mg/day for at least 6 weeks prior to visit 1 and sulfonylurea at a stable dose for 6 weeks prior to visit 1.
[5]Have an HbA1C >7.0% and =10.0%.
[6]Have a body mass index (BMI) between =25 and =45 kg/m2.
[7]Have a history of stable body weight (not varying by >10% for at least 3 months prior to visit 1.
[8]Liver enzyme tests (alanine aminotransferase [ALT]; aspartate aminotransferase [AST]) are not greater than three times of the upper limit of the reference range (as defined by the Lilly-designated laboratory).

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

[9]Are currently taking OAM that is not described above and not allowed with concurrent use of insulin per local product label
[10] Have taken more than 1 week within 1 month prior to the visit 1 any glucose-lowering medications not included in inclusion criteria [3] and [4]
[11]Have taken any insulin other than Glargine within the 3 months prior to visit 1 for more than 1 week.
[12]Are receiving chronic systemic glucocorticoid therapy within 4 weeks prior to the visit 1
[13] Have had a clinically significant history of cardiac disease with functional status that is Class III or IV or considered by the investigator to be exclusionary.
[14]Have had more than 1 episode of major hypoglycemia, as defined in the Abbreviations and Definitions section, within 6 months prior to visit 1
[15]Female subjects with a positive pregnancy test and/or intending to become pregnant or sexually active and not using birth control throughout the study to prevent pregnancy.
[16]Women who are breastfeeding.
[17]Have any of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic or gastrointestinal disease or any other serious disease considered by the investigator to be exclusionary.
[18]Have fasting triglycerides levels > 500mg/dl ( >5.64mmol/l)
[19]Have a history of renal transplantation or are currently receiving renal dialysis.
[20]Have a history of confirmed pancreatitis
[21]Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
[22]Have contraindication or known hypersensitivity or allergy to Exenatide or to any of the product components (including prior withdrawal of Exenatide therapy after experiencing adverse events).
[23]Have had a blood transfusion or severe blood loss within 3 months prior to visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other condition known to interfere with the HbA1c methodology.
[24]Have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes the subject from following and completing the protocol, according to the investigator’s judgment.
[25]Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
[26]Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
[27]Are employed by Lilly or Amylin Pharmaceuticals, Inc. (Amylin)
[28]Have previously completed or been withdrawn from this study after enrollment.
[29]If on metformin and have contraindication to metformin use, including known metabolic or lactic acidosis, or any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis.
[30]Have had a radiologic contrast study performed within 48 hours prior to visit 1.
[31] have any exclusion required by local law

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials